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Background and Purpose  Neurological involvement in Behçet’s disease [neuro-Behçet’s 
disease (NBD)] is uncommon, but it is worth investigating since it can cause substantial dis-
ability. However, difficulties exist in understanding the clinical features of NBD due to regional 
variations and the lack of studies utilizing well-established diagnostic criteria. We therefore 
analyzed the clinical features of patients with NBD based on the recent international consen-
sus recommendation.
Methods  We retrospectively searched electronic databases for patients with Behçet’s disease 
(BD) between 2000 and 2017, and reviewed their medical records. Based on the recent inter-
national consensus recommendation, patients with definite or probable NBD were included.
Results  Of 9,817 patients with the diagnosis code for BD, 1,682 (17.1%) visited the neurology 
clinic and 110 (1.1%) were classified as NBD. Ninety-eight patients exhibited parenchymal 
NBD and 12 exhibited nonparenchymal NBD. Their age at the onset of NBD was 37.6±10.6 
years and the male-to-female ratio was 1.24:1. Brainstem syndrome (43.9%) was the most com-
mon condition in the 98 patients with parenchymal NBD, followed by multifocal (32.7%) and 
spinal cord (12.2%) syndromes. 72.4% exhibited acute NBD and 27.6% exhibited a progressive 
disease course. Frequent manifestations included pyramidal signs (52.0%), headache (45.9%), 
dysarthria (42.9%), and fever (31.6%). A frequent pattern in brain MRI was an upper brainstem 
lesion extending to the thalamus and basal ganglia.
Conclusions  Approximately 1% of the patients with suspected BD exhibited NBD. Neurolo-
gists must understand the clinical characteristics of NBD in order to perform the differential di-
agnosis and management of these patients.
Key Words   neuro-Behçet’s disease, Behçet’s disease, classification, treatment.
Clinical and Radiographic Characteristics 
of Neuro-Behçet’s Disease in South Korea
INTRODUCTION
Behçet’s disease (BD) is a multisystem inflammatory disease of uncertain etiology, with 
clinical features characterized by recurrent oral and genital ulcers, uveitis, and skin lesions.1 
Neurological involvement in Behçet’s disease [neuro-Behçet’s disease (NBD)] has been re-
ported to be less common than other systemic manifestations,2 but NBD can cause sub-
stantial disability. A previous study found that approximately 45% of patients with NBD de-
teriorated to a state requiring unilateral assistance for ambulation or worse within 10 years 
from the onset of neurological symptoms.3 In addition, approximately one-third of pa-
tients with NBD are known to convert to a progressive disease course.3,4
Several difficulties exist in understanding the clinical features of NBD. The prevalence of 
BD shows regional variations, with strikingly high prevalence rates in Middle Eastern and 
Far Eastern countries. In addition, the reported proportion of patients with neurological 
manifestations has varied markedly, from 1.3% to 59%.2,5 Further, the clinical manifesta-
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tions NBD also show racial differences; for example, the in-
cidence of intracranial hypertension is reportedly high in 
the Middle East,6 whereas seizure or optic neuritis appears 
frequently in Western countries.7 In addition, until recently 
there were no well-established diagnostic criteria for NBD, 
and so most previous studies have had to collect patients based 
on applying their own standards.
The present study analyzed the demographic, clinical, and 
imaging features of patients with NBD in South Korea based 
on recently suggested diagnostic criteria for NBD.8 We also 
analyzed the clinical manifestations and course of NBD.
METHODS
Subject enrollment
We retrospectively reviewed the medical records of patients 
with BD who visited the Department of Neurology of Sever-
ance Hospital, Seoul, South Korea. Patients with the diagno-
sis code for BD were identified between January 2000 and 
December 2017, and their medical records were reviewed 
from January 1985 to December 2017. The diagnosis of NBD 
was based on the recent international consensus recommen-
dation.8 The patients were diagnosed as having “definite NBD” 
if they fulfilled the following criteria: 1) displayed a neuro-
logical syndrome recognized as being caused by BD, 2) ex-
hibited characteristic abnormalities of NBD in neuroimaging 
or CSF analysis, and 3) satisfied the International Study Group 
(ISG) diagnostic criteria for BD. The patients were diagnosed 
as having “probable NBD” if they 1) displayed a neurological 
syndrome supported by neuroimaging or CSF analysis that 
did not satisfy the ISG criteria for BD or 2) displayed non-
characteristic neurological symptoms while satisfying the ISG 
criteria for BD. The neurological syndromes recognized as 
being caused by BD included brainstem symptoms/signs, ce-
rebral symptoms/signs, myelopathy, optic neuropathy, any 
combination of the aforementioned symptom/signs (multifo-
cal), and nonparenchymal syndromes. The nonparenchymal 
syndromes included cerebral venous thrombosis, intracranial 
hypertension syndrome, and acute meningeal syndrome. Pa-
tients were included in the present study if they were classified 
as definite or probable NBD. The patients diagnosed with al-
ternative causes for their neurological findings were excluded. 
The Institutional Review Board of Severance Hospital approved 
this study (approval no: 4-2018-0643) and the study was con-
ducted in accordance with the Declaration of Helsinki.
Data collection and definition
Demographic data and clinical features of the patients were 
recorded by reviewing medical records. An attack was de-
fined as an acute onset of neurological symptoms/signs that 
lasted for more than 24 hours. Cases with NBD were classified 
into nonparenchymal (cerebral venous thrombosis, intracra-
nial hypertension syndrome, and acute meningeal syndrome) 
and parenchymal NBD. The clinical course of parenchymal 
NBD was classified into an acute course or a chronic progres-
sive course. Patients were described as having acute NBD when 
they displayed acute focal neurological symptoms, which was 
usually accompanied by CSF pleocytosis. Depending on the 
number of acute attacks, acute NBD was further classified 
into a single episode (single acute attack) and the relapsing-
remitting form (relapsing and remitting course with multiple 
attacks). Patients were classified into the chronic progressive 
type if they displayed the continuous worsening of neurolog-
ical symptoms or signs over a period of months or years. De-
pending on the presence of preceding attack(s), chronic pro-
gressive NBD was classified into the primary progressive form 
(absence of preceding attacks) and the progressive form with 
relapse (one or more attacks during the progression course). 
MRI was performed during an acute attack or at the initial visit 
to the neurology department during the progressive disease 
course. CSF was analyzed in 64 patients.
Statistical analysis
Data are expressed as mean±SD or median [interquartile 
range] values for continuous variables depending on whether 
or not they conformed to a normal distribution. Data are re-
ported as number (percentage) values for categorical vari-
ables. Fisher’s exact test or the chi-square test was used to 
compare categorical variables, and Mann-Whitney test was 
used to compare nonparametric data. A probability value of 
p<0.05 was considered statistically significant. Statistical 




The patient inclusion flowchart is displayed in Fig. 1. There 
were 9,817 patients identified with the diagnosis code for BD 
during the study period, of which 1,682 (17.1%) visited the 
neurology clinic for various reasons. The most-frequent rea-
sons for visiting the neurology department included the eval-
uation and management of headache (47.1%), other pain 
(12.5%), or dizziness (11.0%), or for managing previously di-
agnosed cerebrovascular disease (9.9%), peripheral neu-
ropathy (8.7%), or movement disorders (6.6%). Among the 
1,682 patients with suspected BD who visited the neurology 
clinic, 870 satisfied the ISG criteria for BD, of which 778 had 
alternative diagnoses that explained their symptoms better, 
including primary headache (48.3%), polyneuropathy asso-
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ciated with etiologies other than BD (12.3%), nonspecific diz-
ziness (6.2%), and essential tremor or primary dystonia (3.8%). 
Of the remaining 92 patients satisfying the ISG criteria, 79 
were finally classified as having definite NBD based on ab-
normal neuroimaging and/or CSF findings, and the other 13 
were classified as having probable NBD. Of the 812 patients 
with suspected BD who did not satisfy the ISG criteria, 18 
who had both the characteristic neurological syndrome and 
abnormal neuroimaging and/or CSF findings were classified 
as having probable NBD. Finally, 110 patients were included in 
this study. Their age at the onset of NBD was 37.6±10.6 years 
and the male-to-female ratio was 1.24:1. 
Clinical features of patients with parenchymal NBD
The clinical characteristics of the 98 patients with parenchy-
mal NBD are presented in Table 1. Oral ulceration was ob-
served in 97 (99.0%) patients, skin lesions in 76 (77.6%), geni-
tal ulceration in 66 (67.3%), and ocular manifestation in 57 
(58.2%). The classification of patients with NBD according 
to the clinical syndrome and clinical course is demonstrated 
in Fig. 2. Thirty-two (32.7%) patients exhibited multifocal 
neurological syndrome, 43 (43.9%) exhibited brainstem syn-


































Suspicious Behçet’s disease patients who visited neurology clinic (n=1,682)
ISG criteria (+) (n=870) ISG criteria (-) (n=812)
Suspicious Behçet’s disease from 2000 to 2017 (n=9,817)
Fig. 1. Flowchart of patient inclusion. CSF: cerebrospinal fluid, ISG: International Study Group, NBD: neuro-Behçet’s disease.
Table 1. Baseline characteristics of 110 patients with NBD and 98 pa-






Age at onset of BD, years 27.9±10.2 28.2±10.1
Age at onset of NBD, years 37.6±10.6 37.9±10.6
Sex, male   61 (55.5) 56 (57.1)
Characteristics of BD
Oral ulceration 107 (97.3) 97 (99.0)
Genital ulceration   74 (67.3) 66 (67.3)
Ocular manifestation   59 (53.6) 57 (58.2)
Skin lesions   86 (78.2) 76 (77.6)
Positive pathergy test*     5 (16.1)   4 (13.8)
HLA-B51-positive†   24 (50.0) 19 (46.3)
CSF analysis‡
CSF abnormalities   45 (70.3) 37 (66.1)
Cell count 27.5 [5.8–104.0] 20.0 [4.3–100.3]
Protein concentration 44.0 [31.0–65.0] 45.0 [31.0–65.0]
Glucose 60.0 [52.0–66.5] 61.0 [52.0–67.0]
Data are n (%), mean±SD, or median [interquartile range] values.
*Pathergy test was conducted in 31 of all NBD patients and 29 of pa-
renchymal NBD patients, †HLA-B51 test was conducted in 48 of all NBD 
patients and 41 of parenchymal NBD patients, ‡CSF analysis was per-
formed in 64 of all NBD patients and 56 of parenchymal NBD patients.
BD: Behçet’s disease, CSF: cerebrospinal fluid, NBD: neuro-Behçet’s disease.
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exhibited cerebral syndrome, and 3 (3.1%) exhibited optic 
neuropathy. In terms of the clinical course, 43 (43.9%) expe-
rienced a single episode, 28 (28.6%) exhibited the relapsing-
remitting form, 16 (16.3%) exhibited the primary progressive 
form, and 11 (11.2%) exhibited the progressive form with re-
lapse. Sixty-two clinical relapses were observed in 39 patients, 
and the duration between the relapses was 2.5 [1–4] years. CSF 
was analyzed in 56 patients, and the results were abnormal 
in 37 (66.1%) of them.
The detailed neurological manifestations of patients with 
parenchymal NBD are presented in Fig. 3. Overall, pyrami-
dal signs or symptoms were the most common manifesta-
tion, observed in 51 (52.0%) patients. Headache and fever 
were observed in 45 (45.9%) and 31 (31.6%) patients, respec-
tively. Symptoms or signs associated with brainstem involve-
ment were also commonly observed in the present study, 
with dysarthria in 42 (42.9%) patients, diplopia in 25 (25.5%), 
and ataxia in 22 (22.4%). Memory impairment was the most 
common symptom associated with cerebral hemispheric in-
volvement (22.4%), followed by personality change (11.2%), 
confusion (10.2%), and seizure (9.2%). While headache, par-
esthesia, and fever were relatively common in acute NBD, 
dysarthria, memory impairment, and gait disturbance were 
characteristic of chronic progressive NBD (Supplementary 
Fig. 1 in the online-only Data Supplement).
Clinical features of patients with nonparenchymal 
NBD
Twelve patients were classified as having nonparenchymal 
NBD, of which eight patients (four men and four women) 
exhibited acute meningeal syndrome. The ages at the onsets 
of BD and NBD were 29.5 [18.8–35.8] and 39 [24.5–49.3] 
years, respectively. Frequently presenting symptoms includ-
ed headache (100%), fever (87.5%), and nausea (37.5%). All 
of the patients exhibited CSF pleocytosis. The CSF cell count 
was 96.0 [34.0–105.0]/mm3 and the CSF protein concentra-
tion was 39.8 [36.0–89.0] mg/dL. Seven patients were eval-
uated using brain MRI, which revealed leptomeningeal en-
hancement in two of them. Four patients exhibited venous 
sinus thrombosis. The thrombus was located in the trans-
verse sinus in one patient, the transverse and sigmoid sinuses 
in one, the superior sagittal and transverse sinuses in one, and 
the superior sagittal, transverse, and sigmoid sinuses in one. 
The ages at the onsets of BD and NBD were 19.5 [15.8–21.8] 
and 33.5 [30.5–37.3] years, respectively. Frequently present-
ing symptoms included headache (100%), visual disturbance 
(50%), and nausea (25%). 
Headache in patients with BD
Headache was present in 793 (47.1%) of the 1,682 patients 
with suspected BD who visited the neurology clinic: in 58 



































Parenchymal NBD patients (n=98)
Acute parenchymal NBD (n=71) Chronic progressive parenchymal NBD (n=27)
B  
Fig. 2. Classification of patients with NBD. Classification of 110 patients with NBD based on the clinical syndrome (A) and classification of 98 pa-
tients with parenchymal NBD based on the clinical course (B). NBD: neuro-Behçet’s disease.
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the remaining 1,572 patients with BD (non-NBD). Further, 
89.4% of the patients with BD who visited the neurology de-
partment had alternative diagnoses other than NBD that better 
explained their symptoms, and this was primary headache in 
48.6% of cases. Overall, only 7.3% of the headaches in pa-
tients with suspected BD were attributed to NBD. We fur-
ther compared basic demographic and concomitant neuro-
logical features between the patients with and without NBD 
who had headache. The male-to-female ratio indicated a 
marked female dominance (1:4.6) in patients without NBD 
having headache, whereas there was no significant sex dif-
ference (1:1.1) in patients with NBD having headache (p< 
0.001). Patients with NBD having headache were signifi-
cantly younger (36.7±11.1 years) than those without NBD 
having headache (44.4±11.7 years, p<0.001). Moreover, 86.2% 
of the patients with NBD exhibited other neurological signs, 
whereas these signs were observed in only 7.5% of the pa-
tients without NBD having headache (p<0.001).
MRI findings of patients with parenchymal NBD
Brian MRI was conducted in 87 patients with parenchymal 
NBD. The characteristics of the MRI findings are summa-
rized in Table 2. The most frequent site of involvement was 
the brainstem (67.8%), followed by the white matter (43.7%), 
basal ganglia (41.4%) and thalamus (26.4%). Most of the 
white-matter lesions were located in the deep white matter. 
Only a few patients had lesions in the subcortex or periven-
tricular area. Cortical lesions were observed only in two (2.3%) 
patients. The location of the brain lesions did not differ signif-
icantly between patients with acute NBD and chronic pro-
gressive NBD. Contrast enhancement occurred significantly 
more frequently in patients with acute NBD (p=0.007) than 
in those with chronic progressive NBD, whereas the latter 
were strongly associated with brainstem atrophy (p<0.001). 
Lesions were observed in 11 (52.4%) of the 21 patients who 
underwent spinal cord MRI. Lesions were most frequently 
located in the cervical area, followed by the thoracic and lum-
bar segments. The length of the spinal cord lesion was one 
or two vertebral bodies in two patients, three to five vertebral 
bodies in four patients, and more than five vertebral bodies 
in five patients.
Treatment approach in patients with NBD
Table 3 lists the treatment approaches and prognoses in the 
110 patients with NBD. The duration from the onset of NBD 
to the diagnosis was significantly shorter in patients with acute 
NBD [1.0 (0–5.0) months] than in those with chronic progres-
sive NBD [3.0 (0–15.0) months, p=0.02]. There was no over-
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all difference in treatment between acute NBD and chronic 
progressive NBD. Corticosteroids were most frequently se-
lected as the treatment option: they were used for the initial 
treatment of NBD in 89 (80.9%) patients and were used 
overall in 96 (87.3%) patients. Immunosuppressive or immu-
nomodulating agents were used in 48 (56.4%) patients. Aza-
thioprine was the most common agent, followed by cyclo-
phosphamide and cyclosporine. Seven of the 12 patients who 
received treatment with cyclosporine had been taking the 
medication prior to the NBD onset and continued the treat-
ment for the management of the disease. Cyclosporine was 
primarily used for managing NBD in the remaining five pa-
tients. At the end of the follow-up, the score on the modified 
Rankin Scale was significantly higher in chronic progressive 
NBD [3.0 (3.0–4.0)] than in acute NBD [1.0 (0–3.0), p<0.001].
DISCUSSION
The current study identified the characteristics of patients 
with NBD from a large study population observed over a pe-
riod of 17 years. Patient inclusion criteria were determined 
based on the diagnostic criteria suggested by the recent in-
ternational consensus recommendation.8 Although 17% of 
the patients with suspected BD visited the neurology depart-
ment, the prevalence of NBD was 1.1% among the patients 
with suspected BD. Nearly 90% of the patients with suspected 
BD who visited the neurology department had alternative di-
agnoses, including primary headache. These findings dem-
onstrate the importance of neurologists understanding the ba-
sic characteristics of NBD in order to properly diagnose and 
manage patients with BD exhibiting neurological symptoms.










Cortex 2 (2.3) 2 (3.2)   0 (0) 1.000
White matter 38 (43.7) 29 (46.0)   9 (37.5) 0.473
Subcortex   9 (10.3)   8 (12.7)   1 (4.2) 0.434
Deep white matter 33 (37.9) 25 (39.7)   8 (33.3) 0.585
Periventricular area 7 (8.0) 4 (6.3)   3 (12.5) 0.389
Basal ganglia 36 (41.4) 29 (46.0)   7 (29.2) 0.153
Caudate/putamen 22 (25.3) 15 (23.8)   7 (29.2) 0.607
Internal capsule 27 (31.0) 23 (36.5)   4 (16.7) 0.074
Thalamus 23 (26.4) 18 (28.6)   5 (20.8) 0.464
Brainstem 59 (67.8) 45 (71.4) 14 (58.3) 0.243
Midbrain 46 (52.9) 34 (54.0) 12 (50.0) 0.740
Pons 49 (56.3) 37 (58.7) 12 (50.0) 0.463
Medulla 23 (26.4) 14 (22.2)   9 (37.5) 0.149
Cerebellum 4 (4.6) 3 (4.8)   1 (4.2) 1.000
Spinal cord* 11 (52.4) 10 (15.9)   1 (4.2) 0.277
Cervical 10 (47.6)   9 (14.3)   1 (4.2) 0.272
Thoracic   7 (33.3) 6 (9.5)   1 (4.2) 0.668
Lumbar   3 (14.3) 3 (4.8)   0 (0) 0.558
Optic nerve 3 (3.4) 3 (4.8)   0 (0) 0.558
MRI characteristics
Enhancing lesion† 44 (53.7) 36 (62.1)   7 (29.2) 0.007
Brainstem atrophy 28 (32.2)   7 (11.1) 21 (87.5) <0.001
Tumor-like lesion 3 (3.4) 3 (4.8)   0 (0) 0.558
Data are n (%) values.
*Spinal cord MRI was conducted in 21 patients (14 with acute NBD and 7 
with chronic progressive NBD), †Contrast-enhanced MRI was conducted 
in 82 patients (58 with acute NBD and 24 with chronic progressive NBD).
NBD: neuro-Behçet’s disease.
Table 3. Comparison of treatment approaches between acute NBD and chronic progressive NBD 
Characteristic All (n=110) Acute (n=83) Chronic progressive (n=27) p
Duration from onset of NBD to diagnosis, months 1.0 [0–7.0] 1.0 [0–5.0] 3.0 [0–15.0] 0.020
Overall treatment
Intravenous steroid 54 (49.1) 41 (49.4)    13 (48.1) 0.910
Cyclophosphamide 16 (14.5) 10 (12.0)      6 (22.2) 0.215
Oral steroid 94 (85.5) 70 (84.3)    24 (88.9) 0.757
Azathioprine 31 (28.2) 23 (27.7)      8 (29.6) 0.847
Methotrexate 3 (2.7) 2 (2.4)    1 (3.7) 1.000
Cyclosporine 12 (10.9)   9 (10.8)      3 (11.1) 1.000
Infliximab 2 (1.8) 2 (2.4) 0 (0) 1.000
Use of immunosuppressant or immunomodulating agents* 48 (56.4) 36 (43.4)    12 (44.4) 0.922
Number of immunosuppressants used 1.000
1 38 (34.5) 29 (34.9)      9 (33.3)
2 6 (5.5) 5 (6.0)    1 (3.7)
≥3 4 (3.6) 2 (2.4)    2 (7.4)
Score on modified Rankin scale at the last visit 1.0 [0–3.0] 1.0 [0–2.0] 3.0 [3.0–4.0] <0.001
Data are n (%) or median [interquartile range] values.
*Includes azathioprine, methotrexate, cyclosporine, cyclophosphamide, and infliximab.
NBD: neuro-Behçet’s disease.
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The results of the present study are consistent with previous 
reports in terms of demographic and clinical features. The 
mean age at the onset of NBD was 37.6 years in the present 
study, which is within the range of 25.0–39.8 years reported 
previously.4,5,9-12 High male-to-female ratios for patients with 
NBD have been observed in most of the previous studies, with 
an overall male-to-female ratio of 2.8:1.1 However, lower 
male-to-female ratios have been reported for South Korea, 
ranging from 0.8:1 to 1.8:1,13,14 which may result from the low 
male-to-female ratio for BD in South Korea.15 Thus, the sex 
ratio of 1.2:1 in the present study may reflect both the overall 
male predominance in NBD and the racial characteristics of 
South Korean patients. The frequency of major clinical symp-
toms of BD and the proportion of patients testing positive for 
HLA–B51 are also consistent with previous reports.10-12,16 The 
percentage of positive pathergy test results has varied widely, 
from 8% to 70%, being high mostly in Mediterranean coun-
tries.1,17 In contrast, the proportion of positive pathergy test 
results has been reported to be low in both South Korea and 
Western countries.12,13,18 A pathergy reaction was observed 
in 13.8% of the patients in the present study, which is slightly 
higher than the rate of 6.7% observed previously in South 
Korea.13 
The prevalence of NBD was 1.1% among all of the patients 
with suspected BD, 6.5% among the patients with suspected 
BD who visited the neurology clinic, and 12.6% among the 
patients with BD who fulfilled the ISG criteria and visited 
the neurology clinic. The prevalence of NBD among the pa-
tients with BD was lower than that found in previous pro-
spective studies, which ranged from 5.3% to 14.3%.19-21 This 
discrepancy may have resulted from differences in the ap-
plied inclusion criteria. In contrast to the previous studies 
only including patients who fulfilled the diagnostic criteria 
for BD,19-21 all patients with suspected BD were included in 
the present study regardless of whether or not they satisfied the 
ISG criteria. Since the prevalence of NBD was higher among 
the patients with BD satisfying the ISG criteria (10.6%) than 
among those who did not fulfill the criteria (2.2%), the over-
all prevalence of NBD would have been higher if only the 
patients fulfilling the ISG criteria were included. However, 
we also included the patients who did not satisfy the ISG 
criteria since these patients can be classified as having prob-
able NBD based on the recent international consensus rec-
ommendation.8 In addition, the reported prevalence of NBD 
among patients with BD has varied widely, from 1.3% to 59% 
depending on the study population, definition of NBD, and 
study design.2,5 Although the estimated prevalence of NBD 
has ranged between 5% and 30%,17 several studies—includ-
ing another study from South Korea—have found low prev-
alence rates of NBD ranging from 1.3% to 3.5%.2,13,22
Headache has been reported to be the most common neu-
rological symptom of BD.23-25 Consistently, headache was 
observed in nearly half of the present patients with NBD and 
those with BD without neurological involvement. Although 
headache can present as a sign of NBD, it also frequently 
occurs independently in patients with BD. Previous studies 
of the occurrence of headache in patients with BD found that 
tension-type headache and migraine are common,23-25 as they 
are in the general population. Both the present and previous 
studies found that only 10% of the headache in patients with 
BD is due to NBD.26,27 Most of the headaches in the patients 
with BD are benign, showing no abnormal findings in brain 
MRI.28 Thus, isolated headache in patients with BD is gener-
ally not attributed to neurological involvement in BD.3,4,11,12 
Headache in NBD differs from benign headache, in that nearly 
80% of patients with NBD demonstrate other neurological 
syndromes.3 In addition, we further demonstrated the differ-
ences in the demographic features between the patients with 
and without NBD having headache: the male-to-female ra-
tio was significantly higher and the mean age was lower in 
patients with NBD than in those without NBD. These ob-
servations support the assumption that the headaches expe-
rienced by patients with and without NBD are different dis-
ease entities.
The clinical and radiographic features of NBD generally 
show a characteristic pattern despite some regional differ-
ences being reported. Overall, more than 80% of patients 
with NBD present with the parenchymal form, and approxi-
mately 10% of these patients exhibit spinal cord involve-
ment.1 The prevalence rates of cerebral venous thrombosis 
and optic neuropathy show regional differences. The report-
ed prevalence of cerebral venous thrombosis in Far Eastern 
and European countries has ranged from 0% to 9.1%,10,13,29-31 
whereas it has been higher in the Middle East, ranging up 
to 42%.5 Optic neuropathy has been considered rare in pa-
tients with BD, with a prevalence of less than 5% among those 
with NBD,4,30,31 but this has been observed to be 9% in Cau-
casian patients.7 Regarding parenchymal NBD, the acute 
parenchymal form is more common than the chronic pro-
gressive form, with an approximate ratio of 2.2:1.9,32-34 This 
is similar to the ratio of 2.6:1 observed in the present study. 
Headache and pyramidal signs are the most commonly re-
ported clinical signs, followed by sensory abnormality and 
ataxia.10,16 Although seizure usually occurs in fewer than 5% 
of cases,35 its prevalence has been reported to be as high as 
27% in Caucasian patients.7 Radiographic findings of NBD 
patients characteristically show upper brainstem involvement, 
frequently extending to the basal ganglia and thalamus.14 
Although the white matter is frequently involved, white-mat-
ter lesions show no predilection for the periventricular area.30 
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Brain atrophy was observed in 10–30% of the patients in pre-
vious studies,9,36,37 and was present in 32.2% of the patients in 
the current study. 
The recent international consensus recommendation sug-
gests that intravenous methylprednisolone should be ad-
ministered in an acute attack or relapse.8 It is generally rec-
ommended that steroids should be used for the initial attack, 
with other oral immunosuppressants added if the response 
is inadequate.1 Among oral immunosuppressants, the recent 
international consensus recommendation suggests azathio-
prine as a first-line disease-modifying therapy.8 It is recom-
mended to use cyclosporine with caution due to its potential 
association with the development of CNS complications.38 
However, none of the patients included in the present study 
discontinued cyclosporine treatment following the diagno-
sis of NBD, suggesting that the potential neurotoxicity of cy-
closporine is not widely known among physicians. Although 
no difference in therapeutic agents was found between acute 
NBD and chronic progressive NBD, those patients with 
chronic progressive NBD displayed both a progression of 
the neurological symptoms and a worse score on the modi-
fied Rankin Scale compared to subjects with acute NBD at 
the last visit. This finding suggests that the currently recom-
mended therapeutic guideline is ineffective in the treatment 
of the chronic progressive form of NBD. The findings of 
some recent studies suggest that methotrexate or infliximab 
is effective against the progressive form of NBD.39,40 The du-
ration from the onset of NBD to a diagnosis was signifi-
cantly longer for the chronic progressive form. It has been 
suggested that the early initiation of treatment is associated 
with better outcomes.5 However, the initial diagnosis is fre-
quently delayed in the progressive form of NBD due to its 
insidious onset, and it is unclear whether early treatment of 
these patients influences the prognosis.
Several limitations existed in the present study. First, in-
formation regarding the presence of neurological symptoms 
in the remaining 8,135 patients with suspected BD who did 
not visit the neurology department could not be obtained, 
and it is possible that some of these patients exhibited NBD. 
Second, the serum and CSF levels of various disease mark-
ers were not evaluated in the present study. Recent studies 
have demonstrated that interleukin-6, tumor necrosis factor 
alpha, and matrix metallopeptidase-9 levels are associated 
with disease activity in patients with NBD,32,41,42 and measur-
ing these markers may have provided useful information for 
the diagnosis of NBD. Third, although the acute meningeal 
syndrome was classified as nonparenchymal NBD following 
the recent international consensus recommendation, micro-
scopic inflammatory lesions may be present in the brain pa-
renchyma. In addition, the acute meningeal syndrome could 
not be fully discriminated from simple headache in NBD in 
the present investigation, considering that CSF was not ana-
lyzed in each patient. However, given that it is not practically 
feasible to perform a CSF analysis for all NBD patients with 
headaches, we classified headaches as primary headaches 
despite CSF analysis not being conducted.
In conclusion, the present study has revealed the clinical 
features of a large population of patients with NBD in South 
Korea. Approximately 1% of the patients with suspected BD 
exhibited NBD, and most of the patients who visited the 
neurology department had alternative diagnoses that pro-
vided a better explanation of their symptoms. These findings 
indicate the importance of neurologists understanding the 
clinical and radiographic characteristics of NBD in order to 
perform the differential diagnosis and management of these 
patients.
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